ICON Public Limited Company (NASDAQ:ICLR) is among the cheap healthcare stocks to buy heading into 2026. On December 4, BMO Capital maintained its ‘Market Perform’ rating and $175 price target on ICON Public Limited Company (NASDAQ:ICLR) after the analyst call with management. During the call, many topics were discussed, including senior executive change and ongoing trends surrounding cancellations.
The analyst also assessed the company’s dynamics in functional work relative to its full-service offerings, along with its plans to increase investments in automation and agentic AI. Additionally, the call discussed the higher pass-through revenue and how it could influence margins in the times ahead, the analyst stated.
Photo by Akram Huseyn on Unsplash
According to TheFly, BMO Capital started its coverage on ICON Public Limited Company on November 13, with a ‘Market Perform’ rating and $175 price target. In that update, the analyst noted that the company’s cancellations will remain elevated in the upcoming quarters. The analyst further added that the company is probably through the worst period now.
Overall, ICON Public Limited Company has a ‘Buy’ or equivalent rating from most of the analysts covering the stock. With a one-year median price target of $213.50, the stock has an upside potential of nearly 15%.
ICON Public Limited Company is an Ireland-based clinical research organization that offers outsourced development and commercialization services. Founded in 1989, the company is committed to delivering leading clinical research solutions.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
